PDF(Pubmed)
Abstract：
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease that affects over 30% of the world\'s population. For decades, the heterogeneity of non-alcoholic fatty liver disease (NAFLD) has impeded our understanding of the disease mechanism and the development of effective medications. However, a recent change in the nomenclature from NAFLD to MASLD emphasizes the critical role of systemic metabolic dysfunction in the pathophysiology of this disease and therefore promotes the progress in the pharmaceutical treatment of MASLD. In this review, we focus on the mechanism underlying the abnormality of hepatic lipid metabolism in patients with MASLD, and summarize the latest progress in the therapeutic medications of MASLD that target metabolic disorders.
摘要：
代谢功能障碍相关的脂肪变性肝病（MASLD）是慢性肝病的主要原因，影响了世界上30％以上的人口。几十年来,非酒精性脂肪性肝病(NAFLD)的异质性阻碍了我们对疾病机制的理解和有效药物的开发.然而,最近从NAFLD到MASLD的术语变化强调了全身代谢功能障碍在该疾病的病理生理学中的关键作用,因此促进了MASLD药物治疗的进展.在这次审查中,我们关注MASLD患者肝脂代谢异常的潜在机制，并总结了针对代谢紊乱的MASLD治疗药物的最新进展。
